Background: Granulocyte colony-stimulating factor (G-CSF) promotes the survival and function of neutrophils. G-CSF is also a neurotrophic factor, increasing neuroplasticity and suppressing apoptosis. Methods: We analyzed G-CSF levels in 197 patients with probable Alzheimer's disease (AD) and 203 cognitively normal controls (NCs) from a longitudinal study by the Texas Alzheimer's Research and Care Consortium (TARCC). Data were analyzed by regression with adjustment for age, education, gender and APOE4 status. Results: Serum G-CSF was significantly lower in AD patients than in NCs ( ␤ = -0.073; p = 0.008). However, among AD patients, higher
Introduction
Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor that helps regulate the mobilization of bone marrow progenitor cells and promotes neuroprotection and neurogenesis [1, 2] . G-CSF is produced by immune cells, particularly macrophages, as well as endothelial cells. Human G-CSF exists as a 174-or 180-amino-acid-long protein, with the 174-amino-acid form being more abundant and more active [3] . The G-CSF receptor is present on hematopoietic cells of the bone marrow and, when activated by G-CSF, initiates the proliferation and differentiation of progenitor cells into mature granulocytes [1] . The G-CSF receptor is also expressed by neurons in the brain and spinal cord, enabling G-CSF to act as a neurotrophic factor. In the central nervous system, G-CSF induces neurogenesis, counteracts apoptosis and increases neuroplasticity [4, 5] .
In rodent models of Alzheimer's disease (AD), G-CSF treatment decreased the amyloid burden in the brain [6, 7] , reversed cognitive impairment [7] and reduced chronic inflammation [8] . In other studies, G-CSF administered to mice following ischemic injury has been shown to stimulate the proliferation of microglia [9] .
In the present study, we sought to determine whether the serum G-CSF level significantly differs between AD and control subjects and whether serum G-CSF levels are correlated with clinical measures of disease severity.
Methods

Participants
Participants included 400 individuals (197 diagnosed with probable AD and 203 cognitively normal controls; NCs) enrolled in the Texas Alzheimer's Research and Care Consortium (TARCC) longitudinal research cohort. The methodology of the TARCC project has been described in detail elsewhere. Briefly, each participant completed an annual examination consisting of a medical examination, interview, blood draw and neuropsychological testing at one of the five TARCC sites. The TARCC core neuropsychological battery consists of commonly utilized instruments in AD clinical/research settings along with measures assessing global functioning, i.e. the Mini-Mental State Examination (MMSE) [10] and the Clinical Dementia Rating (CDR) scale [11] . These data were reviewed by each site's consensus committee, and a diagnosis was assigned according to NINCDS-ADRDA criteria [12] . NCs were judged to be within normal limits on neuropsychological testing by consensus review. Participants with AD were largely in the mild-to-moderate range. The TARCC project has Institutional Review Board approval at all member institutions, and all participants and/or caregivers signed written informed consent documents.
Assays
Non-fasting samples were collected in serum-separating tubes during clinical evaluations, allowed to clot at room temperature for 1 h, centrifuged, aliquoted and stored at -80 ° C in polypropylene vials. Frozen samples were sent to Rules Based Medicine (www.rulesbasedmedicine.com, Austin, Tex., USA), where they were thawed for assay without additional freeze-thaw cycles. Rules Based Medicine conducted a multiplex immunoassay via their human Multi-Analyte Profiling (human MAP) technology. Multiple proteins, including G-CSF, were quantified through multiplex fluorescent immunoassay utilizing colored microspheres with protein-specific antibodies. For G-CSF, the least detectable dose was 5 pg/ml, inter-run coefficient of variation was ! 10%, dynamic range was 1-5,000 pg/ml, overall spiked standard recovery for serum was 70% and cross-reactivity with other human MAP analytes was ! 1%. Assays conducted by this company utilizing this platform, including TARCC data, have been published elsewhere [13, 14] .
Analyses
Statistical analyses were conducted using SPSS version 19.0 (IBM). Unadjusted analyses were conducted by either t test for continuous or Mann-Whitney U test for categorical variables. Serum G-CSF levels were compared across diagnostic categories (AD vs. NC), and associations between G-CSF levels and disease severity (MMSE and CDR scores) were assessed by multivariate regression. All regression models included age, sex, years of education, race and APOE4 carrier status as covariates. Statistical significance was declared for p values ! 0.05. In follow-up analyses, the sample was stratified on APOE4 carrier status (-/-vs. -/+ and +/+), and the analyses described above were repeated.
Results
Demographic characteristics of the study population are shown in table 1 . Relative to controls, AD patients did not significantly differ with respect to sex, race or Hispanic ethnicity; however, they were significantly older (median age, 79 vs. 70 years; p ! 0.001), less educated (median years of education, 14 vs. 16; p ! 0.001) and more likely to carry one or more copies of the APOE 4 allele (APOE4 carriers, 13.7 vs. 2.5%; p ! 0.001). Age , education and G-CSF concentration were analyzed as continuous variables. Odds ratios are for each additional year of age and year of education. Age , education and G-CSF were analyzed as continuous variables. APOE4 status was determined by the carriage of at least one APOE4 allele. 
Median serum G-CSF levels were significantly lower in AD cases compared to controls (8.1 vs. 9.9 pg/ml, respectively; table 1 ). G-CSF remained significantly associated with diagnostic category ( ␤ = -0.073; p = 0.008) following adjustment for age, sex, education and APOE status ( table 2 ) . To test for residual confounding by the APOE4 allele, an analysis was run after stratification of the sample on APOE4 status. Serum G-CSF was not significantly associated with disease status in either the APOE4-positive or APOE4-negative group. However, the p values were marginal (0.053 and 0.077 in APOE4-negative and APOE4-positive individuals, respectively), and the trends were consistent with those observed in the unstratified sample (data not presented).
Among AD participants only (n = 197), higher serum G-CSF levels were negatively associated with lower (worse) scores on the MMSE ( ␤ = -0.178; p = 0.014; table 3) and posi- Age , education and G-CSF were analyzed as continuous variables. APOE4 status was determined by the carriage of at least one APOE4 allele. In post-hoc analyses, serum G-CSF levels were tested for association with individual neuropsychiatric test score by multivariate logistic regression. Serum G-CSF concentration was significantly associated with only digit span among AD participants and delayed logical memory among controls (table 6) . In an attempt to resolve the impact of a number of key processes that have been shown to be important to AD pathology, we performed a set of stratified analyses. First, we selected proteins that were representative of inflammation (Creactive protein; CRP), coagulation (thrombopoietin; THP) and neurotrophic factors (brain derived neurotrophic factor; BDNF). Next, we stratified the participants based upon tertiles for each of these proteins. Finally, we evaluated the association between G-CSF and diagnostic status (AD vs. NC) for participants within each group. Serum G-CSF levels were significantly associated with diagnostic status for participants in the mid-tertile for THP and BDNF. In contrast, G-CSF was associated with diagnostic status only for participants in the high-tertile for CRP (table 7) .
Discussion
In addition to hematopoietic functions, G-CSF has a number of neuroprotective effects. With respect to AD, G-CSF increases the number of microglia, decreases ␤ -amyloid deposition and reverses cognitive impairment in a mouse model [15, 16] . In the present work, we sought to determine whether serum levels of G-CSF are associated with a diagnosis of AD or with disease severity among individuals with a diagnosis of probable AD.
In our primarily Caucasian cohort of individuals with a diagnosis of probable AD and NCs from Texas, we observed significantly lower serum levels of G-CSF protein among AD cases than controls. This observation is in agreement with others [17] . In follow-up analyses in the same cohort, we observed a significant positive association between serum G-CSF and disease severity, as measured by MMSE and CDR scores.
In agreement with the present study, Laske et al. [17] reported lower plasma G-CSF levels in early AD subjects relative to controls. Furthermore, these authors observed that, among AD patients, plasma G-CSF showed a significant inverse correlation with amyloid-␤ (A ␤ 1-42) levels in cerebrospinal fluid. Our results in a larger cohort confirm part of this prior work as we observed a significantly lower level of serum G-CSF among AD patients, compared to NCs. However, in contrast to Laske et al. [17] , we found that increased serum G-CSF was significantly associated with greater disease severity. This difference between the present findings and those of Laske et al. [17] may be due to statistical power and sample size issues. While the previously published study analyzed samples from a total of 100 subjects (50 AD cases, 50 NCs), our results were based on 400 participants. Agreement in the direction of the association between G-CSF levels and increased disease severity among AD participants increases confidence in the results of the present study.
Other researchers, including ourselves, have observed an impact of APOE4 status on associations between various biomarkers and disease status [18] . However, in this instance, carriage of the APOE4 allele did not seem to influence the results. Although stratification of the sample negatively affected the tests by reducing the sample size and hence statistical power, all trends were in the same direction in both stratified and unstratified analyses.
Conclusions
In light of the neurotrophic and neuroprotective role of G-CSF, our results are consistent with the hypothesis that reduced G-CSF abundance contributes to AD pathology. Taken together, these observations raise the possibility that G-CSF is dysregulated early in the disease process and that the elevation in G-CSF observed in more advanced disease may represent a compensatory response. Future work by TARCC scientists will investigate this possibility through the analysis of longitudinal samples collected from the same participants over several years. These findings have implications for the design of clinical trials of G-CSF for the prevention or treatment of AD.
